The estimated Net Worth of Ii Robert C. Goeltz is at least $1.12 Milion dollars as of 2 January 2024. Mr Goeltz owns over 2,004 units of Arcus Biosciences Inc stock worth over $879,572 and over the last 9 years he sold RCUS stock worth over $241,024.
Mr has made over 14 trades of the Arcus Biosciences Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 2,004 units of RCUS stock worth $40,080 on 2 January 2024.
The largest trade he's ever made was exercising 21,517 units of Arcus Biosciences Inc stock on 20 March 2017 worth over $96,181. On average, Mr trades about 2,887 units every 93 days since 2016. As of 2 January 2024 he still owns at least 51,831 units of Arcus Biosciences Inc stock.
You can see the complete history of Mr Goeltz stock trades at the bottom of the page.
Robert C. Goeltz II is the Principal Financial & Accounting Officer and CFO at Arcus Biosciences Inc.
Mr II is 48, he's been the Principal Financial & Accounting Officer and CFO of Arcus Biosciences Inc since . There are 14 older and 1 younger executives at Arcus Biosciences Inc. The oldest executive at Arcus Biosciences Inc is Yasunori Kaneko, 66, who is the Lead Independent Director.
Ii's mailing address filed with the SEC is C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD, CA, 94545.
Over the last 7 years, insiders at Arcus Biosciences Inc have traded over $12,714,957 worth of Arcus Biosciences Inc stock and bought 22,383,260 units worth $566,530,309 . The most active insiders traders include Patrick Machado, Sciences, Inc. Gilead oraz Harbor Master Investors (Ca.... On average, Arcus Biosciences Inc executives and independent directors trade stock every 32 days with the average trade being worth of $5,400,635. The most recent stock trade was executed by Alexander Azoy on 13 August 2024, trading 1,357 units of RCUS stock currently worth $20,314.
arcus biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the san francisco bay area, in the heart of the world’s largest biotechnology research hub. unlike many other organizations, we view the drug discovery process as one that requires equal parts of technology and art, science and elegance, not as a commodity that can be outsourced. for this reason, we have assembled and are continuing to build an internal team of uniquely qualified individuals with extraordinary knowledge, skills and drive. arcus is rapidly establishing a portfolio of novel therapeutics encompassing both small molecules and biologics that target various facets of the immune system implicated in pathology or modulation of the cellular processes of cancer. these new drugs will then be
Arcus Biosciences Inc executives and other stock owners filed with the SEC include: